NFKB1 and prostate carcinoma: At 312.5 μg/mL, these compounds suppressed LPS-stimulated proliferation of PC-3 cells, inhibited activation of NF-κB and mitogen-activated protein kinase p38 in LPS-stimulated PC-3 cells and inhibited inflammation-associated STAT3 activation and proliferation, migration and invasion in PC-3 androgen-insensitive prostate cancer cells [152].